Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001549595-24-000106

Chief Scientific Officer sold 3,408 shares at $20.67 ($70,436)

  • Chief Scientific Officer acquired 8,957 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Hansen Gwenn · Chief Scientific Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2024-07-30 Exercise or conversion : show line 1 in the form +3,207 42,808 D
2024-07-30 Exercise or conversion : show line 2 in the form +2,000 44,808 D
2024-07-30 Exercise or conversion : show line 3 in the form +3,750 48,558 D
2024-07-30 Sale : show line 4 in the form −3,408 $20.67 $70,436 45,150 D
Open-market sales · 3,408 sh · avg $20.67 · $70,436

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2024-07-30 Exercise or conversion : show line 5 in the form Restricted Stock Units −3,207 19,241 D
2024-07-30 Exercise or conversion : show line 6 in the form Restricted Stock Units −2,000 14,000 D
2024-07-30 Exercise or conversion : show line 7 in the form Restricted Stock Units −3,750 41,250 D
Loading xslF345X05/wk-form4_1722380775.xml…